BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third

Feb.13
BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
Reuters reported that British American Tobacco (BAT) CEO Tadeu Marroco said a potential U.S. move to block imports of some disposable vapes could reduce the market for unregulated e-cigarettes by as much as a third, though any impact is unlikely before 2027.

 

Key Takeaways

 

  • BAT CEO said a U.S. import block could cut unregulated vape sales by roughly a third; impact unlikely before 2027
  • BAT estimates unregulated devices make up about 70% of U.S. e-cigarette sales
  • BAT has two active ITC cases seeking to block imports of unregulated devices
  • BAT expects a full ITC determination in March, followed by a 60-day presidential review
  • CEO said long supply chains and inventories would delay material impact until early next year; he also flagged a possible FDA programme testing a different approach, potentially including flavoured vapes

 

 


 

2Firsts, Feb 13, 2026 – 

 

According to Reuters, by Emma Rumney (Emma Rumney), British American Tobacco (BAT) CEO Tadeu Marroco (Tadeu Marroco) said a potential U.S. move to block imports of some disposable vapes could cut the booming market for unregulated e-cigarettes by as much as a third, though any impact is unlikely before 2027.

 

The report said tobacco giants including BAT and U.S. Marlboro-maker Altria (Altria) have spent years fighting a flood of mostly Chinese-made vapes that lack U.S. authorisation for sale but have still come to dominate the world’s largest market for smoking alternatives.

 

BAT estimates unregulated devices make up about 70% of U.S. e-cigarette sales, hitting both its vape and traditional tobacco businesses, the report said. It added that BAT has two active cases at the U.S. International Trade Commission (ITC), seeking to block imports of unregulated devices.

 

The report noted that last year an ITC judge ruled in BAT’s favour in a patent dispute and recommended a general exclusion order that would block disposable vapes infringing its patents. BAT said alongside annual results that it expects a full ITC determination in March, followed by a 60-day presidential review.

 

Marroco told Reuters that such a block could have a meaningful impact on the market, which he defined as a drop to below 50% of industry sales, or by roughly a third, though he said the scale was hard to predict. He also warned that a long U.S. supply chain and large inventories would delay any effect, adding that even with ITC support it would not be until early next year that there would be a material impact.

 

Marroco also said he would not be surprised if the U.S. Food and Drug Administration (FDA) launched a programme to test a different approach to vapes, potentially including flavoured vapes. The report added that after years of rejecting most applications for new nicotine products, the FDA has looked to speed up or streamline its processes.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Russia’s Kirov seizes unmarked vape liquids worth over  $13,000
Russia’s Kirov seizes unmarked vape liquids worth over $13,000
Police in Kirov, Russia, seized unmarked nicotine e-liquids for vapes worth more than 1 million rubles (about $13,000, using 1 ruble = $0.013) in a case involving a 27-year-old entrepreneur. Officers confiscated over 700 bottles from five retail outlets and found more than 8,000 additional units at a warehouse.
Feb.03 by 2FIRSTS.ai
Special Report | Tax Veteran Takes Helm at China’s Tobacco Regulator, Leadership Change Fuels Reform Watch
Special Report | Tax Veteran Takes Helm at China’s Tobacco Regulator, Leadership Change Fuels Reform Watch
China’s tobacco system has appointed a new top internal leader with a long background in public finance and taxation, drawing renewed attention to whether the country’s tobacco monopoly may enter a new phase of reform debate. The appointment itself does not signal a defined policy shift.But it places a veteran fiscal official at the center of a key state sector amid unresolved questions on tax reform, structure, and emerging tobacco products.
Mar.20
Malaysia moves ahead with vape sales ban plan; PMI urges Japan-style differentiated excise taxes
Malaysia moves ahead with vape sales ban plan; PMI urges Japan-style differentiated excise taxes
Malaysia plans to implement a ban or restrictions on e-cigarettes and vaping products as early as mid-2026 and no later than year-end. The head of Philip Morris Malaysia and Singapore said the government should look to Japan’s approach of regulating and taxing different tobacco and nicotine products differently, warning that an outright ban could push demand into illicit channels.
Feb.02
UK Tobacco and Vapes Bill Enters House of Lords Report Stage
UK Tobacco and Vapes Bill Enters House of Lords Report Stage
The Tobacco and Vapes Bill has entered the report stage in the UK House of Lords, with further examination scheduled to begin on February 24, 2026. The legislation aims to create the first “smoke-free generation” by ensuring that individuals who are 15 years old or younger in 2026 can never legally be sold tobacco.
Regulations
Feb.22
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11